Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
Shuo Ma(Nantong University), Andrew W. Roberts(The Royal Melbourne Hospital), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Betty Prine(AbbVie (United States)), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Jacqueline C. Barrientos(Mount Sinai Medical Center), Michael Y. Choi(University of California San Diego), Tanita Mason-Bright(AbbVie (United States)), Wijith Munasinghe(AbbVie (United States)), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), Mary Ann Anderson(The Royal Melbourne Hospital), Su Young Kim(AbbVie (United States)), Constantine S. Tam(The Alfred Hospital)
Cited by 50
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k